Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
67.39(c) 67.34(c) 67.29(c) 67.42(c) 66.92(c) Last
15 019 347 9 541 745 5 426 846 6 247 883 10 771 967 Volume
+3.04% -0.07% -0.07% +0.19% -0.74% Change
More quotes
Financials (USD)
Sales 2021 46 106 M - -
Net income 2021 7 116 M - -
Net Debt 2021 26 832 M - -
P/E ratio 2021 21,0x
Yield 2021 2,91%
Sales 2022 48 116 M - -
Net income 2022 8 890 M - -
Net Debt 2022 16 920 M - -
P/E ratio 2022 16,5x
Yield 2022 3,05%
Capitalization 149 B 149 B -
EV / Sales 2021 3,82x
EV / Sales 2022 3,46x
Nbr of Employees 30 250
Free-Float 76,3%
More Financials
Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Ratings of Bristol-Myers Squibb Company
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about BRISTOL-MYERS SQUIBB COMPANY
06/14Exelixis in Clinical Trial Collaboration with Bristol Myers
DJ
06/14Exelixis Working With Bristol-Myers to Launch Early-Stage Study of Potential ..
MT
06/11BRISTOL MYERS SQUIBB  : and Acceleron Present First Results from Phase 2 BEYOND ..
BU
06/10BRISTOL MYERS SQUIBB  : and GRYT Health Evolve Virtual Patient Advocacy Experien..
BU
06/10Bristol Myers Shares Up After Lymphoma Study Meets Objectives
DJ
06/10BRISTOL MYERS SQUIBB  : Cancer Therapy Breyanzi Meets Phase 3 Trial Goals
MT
06/10BRISTOL MYERS SQUIBB  : to Report Results for Second Quarter 2021 on July 28, 20..
BU
06/10BRISTOL MYERS SQUIBB  : Announces Positive Topline Results from Phase 3 TRANSFOR..
BU
06/10Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives
DJ
06/07EXELIXIS  : Announces Positive Phase 2 Results for CABOMETYX (cabozantinib) in C..
AQ
06/07Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis..
AQ
06/04Germany's MorphoSys, Incyte Say Three-Year Data Backing Tafasitamab Combo in ..
MT
06/04EXELIXIS  : Says Phase 3 Trial of Cabometyx in Advanced Renal Cell Carcinoma Sho..
MT
06/04BRISTOL MYERS SQUIBB  : to Take Part in Goldman Sachs 42nd Annual Global Healthc..
BU
06/03BRISTOL MYERS SQUIBB  : Presents Data from CheckMate -648 Showing Opdivo plus Ch..
BU
More news
News in other languages on BRISTOL-MYERS SQUIBB COMPANY
06/04BRISTOL MYERS  : résultats pour le cancer gastro-intestinales
05/19BRISTOL-MYERS SQUIBB  : utiliser l'IA pour développer des médicaments
05/19PLANÈTE BOURSE  : La revue de presse du mercredi 19 mai 2021
05/06Evotec startet weitere Forschungskooperation mit Bristol Myers Squibb
04/29Corona-Pandemie bremst US-Pharmakonzern Bristol-Myers Squibb weiter
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPANY
More recommendations
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | BMY | US1101221083 | MarketScreener
Technical analysis trends BRISTOL-MYERS SQUIBB COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 75,24 $
Last Close Price 66,92 $
Spread / Highest target 34,5%
Spread / Average Target 12,4%
Spread / Lowest Target -7,35%
EPS Revisions
Managers and Directors
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
David V. Elkins Chief Financial Officer & Executive Vice President
Paul von Autenried Chief Information Officer & Executive VP
Rupert J. Vessey Executive VP-Research & Early Development
Joseph E. Eid Senior VP & Head-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY7.88%150 538
JOHNSON & JOHNSON4.48%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.6.76%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.7.82%204 582